The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias.

NOTE: The ADDF's venture philanthropy model means we make investments, not grants, and use all returns from those investments to support our charitable mission. Our terms are comparable with those of other venture investors. When we are working with academic institutions, in exchange for our investment we typically ask for a share of any commercial returns that may arise from the funded research. When working with biotechnology companies, we typically purchase Convertible Notes or equity, though we are also open to structuring royalty and milestone agreements with biotechs.

We have dedicated our funding to several key areas:

  • IND-enabling studies and early-stage clinical trials for novel and repurposed drugs
  • Development and validation of plasma, CSF, neuroimaging and digital biomarkers
  • Clinical trials, comparative effectiveness research, and epidemiological studies that test whether the use or choice of drugs alters the risk for dementia or cognitive decline

Applications are reviewed throughout the year. Check back regularly for additional joint funding opportunities with our partners in non-profits, government, and industry.

THERAPEUTICS FUNDING PROGRAMS

NOW ACCEPTING APPLICATIONS
Upcoming 2024 deadlines
Must be received by 5:00 pm ET on the deadline date.

Letter of Intent
February 5, 2024

Invited Full Proposal
April 8, 2024

Letter of Intent
May 13, 2024

Invited Full Proposal
July 22, 2024

Letter of Intent
September 30, 2024

Invited Full Proposal
December 9, 2024

 

Drug Development RFP
Neuroimaging and CSF Biomarker RFP
Prevention RFP

ADDF/NIH Funding and SBIR/STTR Bridge Funding Opportunities

DIAGNOSTICS ACCELERATOR PROGRAMS

Learn more about the Diagnostics Accelerator here

ACCEPTING APPLICATIONS ON A ROLLING BASIS

Peripheral Biomarkers RFP
Digital Biomarkers RFP

OTHER FUNDING OPPORTUNITIES WITH OUR PARTNERS

Accelerating Drug Discovery for FTD RFP

Letter of Intent
May 13, 2024

Invited Full Proposal
July 22, 2024

ADDF-Harrington Scholar Program RFP 

Letter of Intent
June 3, 2024, 5:00 PM EDT

Full Proposal
August 26, 2024, 5:00 PM EDT

Award decisions are anticipated by March 2025.

Treat FTD Fund: Clinical trials for FTD

Letter of Intent
TBD 2024

Invited Full Proposal
TBD 2024 

CONFERENCE FUNDING

Supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information, email grants@alzdiscovery.org with a brief summary of your conference.

 
 

ADDF FUNDING PORTAL

 
 

 

Stay updated on upcoming deadlines and RFP announcements
Sign up to receive news by email.